Objective-The ability of high-density lipoprotein (HDL) particles to accept cholesterol from peripheral cells, such as lipidladen macrophages, and to transport cholesterol to the liver for catabolism and excretion in a process termed reverse cholesterol transport (RCT) is thought to underlie the beneficial cardiovascular effects of elevated HDL. The liver X receptors (LXRs; LXRα and LXRβ) regulate RCT by controlling the efflux of cholesterol from macrophages to HDL and the excretion, catabolism, and absorption of cholesterol in the liver and intestine. Importantly, treatment with LXR agonists increases RCT and decreases atherosclerosis in animal models. Nevertheless, LXRs are expressed in multiple tissues involved in RCT, and their tissue-specific contributions to RCT are still not well defined. Approach and Results-Using tissue-specific LXR deletions together with in vitro and in vivo assays of cholesterol efflux and fecal cholesterol excretion, we demonstrate that macrophage LXR activity is neither necessary nor sufficient for LXR agonist-stimulated RCT. In contrast, the ability of LXR agonists primarily acting in the intestine to increase HDL mass and HDL function seems to underlie the ability of LXR agonists to stimulate RCT in vivo. Conclusions-We demonstrate that activation of LXR in macrophages makes little or no contribution to LXR agoniststimulated RCT. Unexpectedly, our studies suggest that the ability of macrophages to efflux cholesterol to HDL in vivo is not regulated by macrophage activity but is primarily determined by the quantity and functional activity of HDL. 
C ardiovascular disease (CVD) is a leading cause of death globally, and it is well established that elevated levels of cholesterol in the blood are a major contributor to disease development. 1 Excess plasma cholesterol accumulates in macrophages lodged in blood vessel walls which along with an associated inflammatory response initiate the formation of atherosclerotic lesions. 2 Statin therapy is highly effective for lowering disease-causing low-density lipoprotein (LDL) cholesterol, thereby reducing morbidity and mortality associated with CVD. 3 Nevertheless, the residual risk for major cardiac events remains high for patients receiving LDLlowering therapies prompting the search for complementary therapeutic approaches. 4 Epidemiological studies have demonstrated that levels of high-density lipoprotein (HDL) cholesterol are inversely associated with CVD suggesting the potential therapeutic benefit of raising HDL. 5 Recent clinical trials with cholesteryl ester transfer protein (CETP) inhibitors and niacin, however, have failed to demonstrate clinical benefits of increasing HDL cholesterol. 6, 7 The clinical trial results have led to the suggestion that HDL functionality, rather than the absolute mass of HDL cholesterol, may be a more accurate indicator for CVD risk. 8, 9 The ability of HDL to promote cholesterol efflux from macrophage foam cells within atherosclerotic lesions was one of its earliest recognized functions. 10, 11 Importantly, cholesterol efflux from foam cells has been shown to increase macrophage egression and to reduce lesion burden in animal models of CVD. [12] [13] [14] Measuring the dynamic rate of macrophage cholesterol efflux, therefore, may be a better predictor of the antiatherogenic effects of novel HDL-targeted therapies. 15 The movement of cholesterol from peripheral cells such as macrophages to HDL constitutes the first step in a process termed reverse cholesterol transport (RCT). HDLderived cholesterol is then trafficked to the liver where it is catabolized or excreted to the bile. 16, 17 Recent studies have also described hepatic-independent pathways for cholesterol secretion. 18 Studies in animal models indicate that measurements of RCT can strongly predict the effect of genetic and pharmacological manipulations on atherosclerosis. 19 Similarly, in humans, an inverse relationship has been uncovered between the ability of patient sera to accept cholesterol from macrophages in vitro and measurements of carotid intima-media thickness with cholesterol acceptor capacity being a strong predictor of coronary disease status. 15 The use of in vitro measurements of plasma cholesterol acceptor activity for predicting CVD as well as the proteins/particles
Integral to the regulation of RCT are the liver X receptors (LXRs), LXRα (NR1H3) and LXRβ (NR1H2), which are members of the nuclear hormone receptor superfamily of ligand-activated transcription factors. Studies using genetic knockouts and synthetic agonists have defined important roles for LXRs in the control of cholesterol homeostasis and fatty acid metabolism. [22] [23] [24] Treatment of animals with LXR agonists results in changes in gene expression promoting the efflux of cholesterol from peripheral cells such as macrophages, the secretion of cholesterol from the liver, and the inhibition of cholesterol absorption in the intestine. 22 Importantly, the endogenous ligands for LXRs are oxidized forms of cholesterol (oxysterols) that increase coordinately with intracellular cholesterol levels, thus allowing these receptors to act as sensors to maintain appropriate cholesterol levels throughout the body. 25, 26 At the molecular level, LXRs control macrophage cholesterol efflux by regulating expression of genes encoding the ATP-binding cassette (ABC) transporters ABCA1 and ABCG1 as well the gene encoding apolipoprotein E. 22 Upregulation of ABCA1 and ABCG1 results in increased transfer of intracellular cholesterol to HDL particles, and genome-wide association studies have linked both transporters to HDL cholesterol levels in humans. 27, 28 Mutations in the human ABCA1 gene results in a genetic syndrome referred to as Tangier disease. Patients with Tangier disease characteristically present with little or no HDL and massive accumulation of cholesterol in lymph tissues and are at increased risk for atherosclerosis. 19, 29, 30 LXR also regulates expression of ABCG5 and ABCG8, 2 half-transporters that dimerize to form an additional cholesterol transporter. 31, 32 Expression of ABCG5/ABCG8 is largely restricted to the liver and intestine, where these proteins function to promote the excretion of cholesterol (liver) and limit cholesterol absorption (intestine). 33 Genetic deletion of ABCG5/G8 or deletion of LXRα in the liver largely blocks the ability of LXR agonists to stimulate fecal excretion of cholesterol. 34, 35 Thus, activation of LXRs promotes a net movement of cholesterol from the periphery out of the body. Not surprisingly, LXR agonists decrease atherosclerosis in animal models of CVD. 34, [36] [37] [38] Treatment with LXR agonists also increases plasma HDL cholesterol, 34, 39 suggesting that LXRs can regulate RCT in both a cell autonomous fashion, by controlling the transporters required to mobilize intracellular cholesterol, as well as in a nonautonomous fashion by regulating the amount of cholesterol acceptor in plasma. Interestingly, the ability of LXR agonists to increase HDL cholesterol levels is largely mediated by the induction of ABCA1 expression in the intestine. 34, 40 Not unexpected then is the observation that an intestinal-specific LXR agonist increases RCT. 41 Although LXR agonists seem to act in macrophages, the liver, and the intestines to stimulate RCT, studies using genetic knockouts indicate that macrophages are the major site of LXR agonist-dependent antiatherogenic activity. 38, 42, 43 The atherosclerosis studies therefore led us to question the tissue-specific contributions of LXRs to the regulation of RCT. Combining in vivo measurements with tissue-selective knockouts, we show that the ability of LXRs to regulate HDL quantity and activity is a major driver of RCT. In contrast, macrophage LXR activity is neither necessary nor sufficient. Furthermore, our studies suggest that the ability of macrophages to efflux cholesterol to HDL in vivo is primarily determined by the quantity and functional activity of HDL in the surrounding environment.
Materials And Methods
Materials and Methods are available in the online-only Supplement.
Results

Macrophage LXR Is Not Necessary for LXR Agonist-Dependent RCT
LXR activity in the liver and the macrophage is thought to contribute to RCT, 44 but the relative contribution of LXR at these sites has not been well defined. To determine the contribution of macrophage LXR to RCT, we injected bone marrow-derived macrophages that had been loaded with 3 H-cholesterol in vitro into the peritoneal space of mice and followed the movement of macrophage-derived cholesterol to the plasma and ultimately to the feces as described by Naik et al. 45 For these studies, we used C57BL/6J (LXR + ) and Figure 1A and 1B). When LXR is present only in macrophages (Mac LXR+ /DKO), however, the amount of macrophage-derived cholesterol in the plasma and feces is significantly decreased ( Figure 1A and 1B) . Similarly, the ability of T0901317 to increase the accumulation of macrophage-derived cholesterol in the plasma of Mac LXR+ /DKO mice is decreased by 70% ( Figure 1A) , and agonist-stimulated fecal excretion is completely blocked in these animals ( Figure 1B) . Quantification of ABCA1 mRNA levels in macrophage re-extracted from the peritoneal space at completion of the experiment demonstrates that placing LXR + macrophages into DKO mice does not impair macrophage LXR transcriptional activity ( Figure 1C) . In contrast to the decreased RCT observed in the Mac LXR+ /DKO mice, selective deletion of LXR in macrophages (Mac DKO /LXR + ) has little or no effect on either the accumulation of 3 H-cholesterol in the plasma or the feces ( Figure 1A and 1B) . Little or no differences among the groups are seen when hepatic levels of 3 H-sterols were examined ( Figure I in the online-only Data Supplement). To further address the contribution of macrophage LXR activity to the ability of LXR agonists to increase the accumulation of macrophage-derived cholesterol in the plasma, we examined 3 H-cholesterol levels in vehicle-and T0901317-treated Mac LXR+ /LXR + and Mac DKO / LXR + mice at 30, 60, and 90 minutes after introducing radiolabeled macrophage into the peritoneal space. As shown in Figure 1D , pretreatment of mice with T0901317 significantly increases 3 H-cholesterol in the plasma by 60 minutes. Even at these short time points, however, the LXR genotype of the macrophages has no effect on the response to agonist treatment. The observation that LXR macrophage activity does not seem to play a role in the accumulation 
/Lxrβ
−/− macrophages. 46 In the absence of agonists, LXRs repress transcription by interacting with corepressors and this activity is lost on genetic deletion. 46 A similar upregulation of ABCA1 expression is observed in DKO macrophages recovered from the peritoneal space of LXR + mice after in vivo RCT experiments ( Figure 1C ).
HDL Levels and Adipose Activity Drive LXR Agonist-Dependent RCT
LXR agonists are known to increase HDL cholesterol predominately by increasing expression of ABCA1 in the intestine. 40 Consistent with an LXR agonist-dependent increase in HDL cholesterol (Table) , plasma from T0901317-treated C57BL/6J (LXR + ) mice has increased cholesterol acceptor activity in vitro when 3 H-cholesterol-loaded RAW264.7 cells are used as donor macrophages. The effect of agonist, however, is lost when plasma from DKO animals is used ( Figure 2A ). To further address the contribution of HDL to macrophage efflux, a similar series of in vitro efflux experiments were performed using fast liquid protein chromatography (FPLC)-purified HDL particles ( Figure 2B ). For experiments with FPLC-purified HDL, peak HDL fractions were pooled ( Figure II in the online-only Data Supplement) and normalized by the amount of apolipoprotein A1 (APOA1) as determined by Western blotting ( Figure IIIA in the onlineonly Data Supplement). Using APOA1 as a relative measure for particle number, HDL from agonist-treated C57BL/6J mice accepts greater amounts of macrophage cholesterol compared with DKO mice ( Figure 2B ). Together, these experiments show that LXR agonist treatment increases both HDL mass and HDL function. During the course of in vivo RCT experiments, it is likely that macrophage-derived 3 H-cholesterol incorporates into cells and tissues throughout the body. Thus, along with increasing the cholesterol acceptor activity of HDL, LXR agonists may also increase the amount of cholesterol in plasma by promoting efflux from other tissues via transcriptional upregulation of ABCA1, ABCG1, and apolipoprotein E. To address the possible contributions of different tissues to LXR agonist-stimulated RCT, radiolabeled LXR + macrophages were introduced into vehicle-and T0901317-treated LXR + mice (Mac LXR+ / LXR + ) and multiple tissues were harvested at 48 hours postinjection to determine whether agonist treatment promotes a net loss in tissue-associated 3 H-sterols. As shown in Figure 2C , a significant agonist-dependent decrease is observed in white adipose (gonadal fat pad) suggesting that fat tissue may make an important contribution to LXR-stimulated accumulation of cholesterol in the plasma and feces. T0901317-dependent changes in 3 H-sterol levels were not observed in other tissues ( Figure 2C) . Importantly, the decrease in adipose 3 H-sterol levels could result from increased LXR transcriptional activity in fat cells, the improved acceptor activity of HDL, or both.
Diet-Dependent Regulation of Liver LXR Activity and RCT
We have previously determined under severe hyperlipidemic conditions (Ldlr −/− mice on Western diet) that liver-specific /Lxrβ -/-(DKO) mice (n=5-6/group) were treated for 5 days with vehicle or 10 mg/kg T0901317, and in vitro macrophage cholesterol efflux was measured as described in Materials and Methods in the online-only Data Supplement using 3 H-cholesterollabeled Raw264.7 cells that were incubated with 0.03% pooled plasma (A) or fast liquid protein chromatography-purified HDL (B). Efflux data are representative of 3 independent experiments. C, 3 H-cholesterol and acetylated low-density lipoprotein-loaded C57BL6/J bone marrow-derived macrophages were injected into C57BL6/J mice treated for 3 days with or without 10 mg/kg T0901317 (n=6/group), and the amount of 3 H-sterol in tissues was determined as described in the Materials and Methods in the online-only Data Supplement. Mice continued to receive vehicle or T0901317 treatment for the duration of the experiment. All data are expressed as mean±SEM. *Statistically significant difference between vehicle-and T0901317-treated animals of the same genotype (P≤0.05%). †Statistically significant difference between C57BL6/J and DKO with the same treatment (P≤0.05%). CPM indicates counts per minute. deletion of LXRα impairs the accumulation of macrophagederived cholesterol in both the plasma and the feces. 34 To further investigate the contribution of liver LXR activity to RCT, liver-specific knockout LXRα (LivKO) mice 34 and floxed littermate controls (carrying the floxed LXRα allele without albumin Cre recombinase) were placed on a standard chow diet with or without 0.2% cholesterol. LXRα is the major LXR subtype expressed in the liver, 47 and the ability of T0901317 to increase plasma triglycerides and to induce expression of hepatic ABCG5, ABCG8, and ABCA1 is significantly impaired in LivKO mice 34 (Table and Figure  IV in the online-only Data Supplement). After 4 weeks on diet, plasma total cholesterol increases 30% to 50% in both LivKO and littermate control groups fed the 0.2% cholesterol diet (Table) . Consistent with published data, the 0.2% cholesterol diet also significantly increases hepatic cholesterol in LivKO mice attributable to impaired fecal excretion and decreased bile acid synthesis 34, 47 ( Figure (Figure 3A) , indicating that liver LXRα activity is not required for agonists to increase the accumulation of 3 H-cholesterol in the plasma. On the contrary, the ability of LXR agonists to increase fecal sterol excretion is completely lost in LivKO mice ( Figure 3B ), a result consistent with decreased agonist-dependent regulation of ABCG5 and ABCG8 in the livers of these animals ( Figure IV in the online-only Data Supplement). Interestingly, exposure to the 0.2% cholesterol diet impairs both LXR agonist-dependent plasma and fecal cholesterol accumulation in LivKO mice relative to controls ( Figure 3C and 3D) . Thus, dietary cholesterol uncovers a critical role for hepatic LXR activity in controlling the accumulation of macrophage-derived cholesterol in plasma. The ability of LXR agonists to increase HDL cholesterol levels in LivKO mice is also sensitive to dietary cholesterol ( Figure 4A and Table) despite similar increases in the intestinal mRNA levels of ABCA1 ( Figure VI in the online-only Data Supplement). Furthermore, a dietary cholesterol-dependent decrease in cholesterol acceptor activity is also observed when FPLC-purified HDL particles isolated from T0901317-treated LivKO mice are compared with HDL particles from littermate controls in vitro ( Figure 4B ; see Figures II and IIIC and IIID in the online-only Data Supplement for FPLC profiles and APOA1 levels). The reason(s) why the cholesterol enriched diet impairs the ability of LXR agonist treatment to increase HDL mass and function remains to be determined. Nevertheless, the failure of T0901317 to modulate HDL levels and functional activity in cholesterol-fed LivKO mice supports the hypothesis that the ability of LXR agonists to promote the accumulation of macrophage-derived cholesterol in plasma is largely derived from systemic effects on HDL and independent of macrophage LXR activity. In vivo reverse cholesterol transport in chow and 0.2% cholesterol diet-fed liver-specific knockout liver X receptor-α (LivKO) mice.
3 H-cholesterol and acetylated low-density lipoprotein-loaded C57BL6/J bone marrow-derived macrophages (BMMs) were injected into floxed or LivKO mice fed standard chow (A and B) or 0.2% cholesterol-supplemented diet (C and D). Animals were treated for 3 days with or without 10 mg/kg T0901317 (n=6/group) before BMM injection, and the amount of 3 H-sterol in plasma (A and C) and feces (B and D) was determined as described in the Materials and Methods in the online-only Data Supplement. Mice continued to receive vehicle or T0901317 treatment for the duration of the experiment. Data are mean±SEM. *Statistically significant difference between vehicle-and T0901317-treated animals of the same genotype (P≤0.05%). †Statistically significant difference between floxed and LivKO mice with the same treatment (P≤0.05%). CPM indicates counts per minute.
Our results indicate that LXR activation can improve the cholesterol acceptor activity of HDL, and this effect is influenced by liver LXR activity in a diet-dependent fashion. As an initial characterization of HDL particle composition, we measured phospholipid levels in the FPLC-purified HDL fractions. Phospholipids are the major components by mass of HDL, and several studies suggest that HDL phospholipid levels are a better predictor of cholesterol efflux than other HDL parameters. 48, 49 As shown in Figure 4C and 4D, T0901317 treatment increases the amount of total phospholipids associated with purified HDL particles (normalized by APOA1 levels) from standard chow-fed floxed and LivKO mice ( Figure 4C ). The increase in HDL phospholipid levels is consistent with studies demonstrating that LXR agonist treatment increased HDL particle size. 34, 50 The effect of agonist treatment on HDL phospholipid levels, however, is lost in 0.2% cholesterol diet-challenged LivKO animals ( Figure 4D ). Phospholipid transfer protein is an HDL-bound protein that plays a major role in regulating HDL size and phospholipid composition through its phospholipid transfer activity. 51 Phospholipid transfer protein mRNA levels have been shown to be regulated by LXR 52 ; however, we did not detect significant differences in plasma phospholipid transfer protein activity between floxed and LivKO mice on either dietary condition (Table I in the online-only Data Supplement).
CETP Decreases MacrophageDerived Cholesterol in Plasma
To test the hypothesis that LXR-dependent regulation of HDL levels and activity plays a major role in driving the accumulation of macrophage-derived cholesterol in plasma, we took advantage of the observation that LXR agonistdependent increases in HDL cholesterol are lost in CETP transgenic mice. 53 CETP facilitates the transfer of cholesterol esters from HDL to apolipoprotein B-containing particles, thereby decreasing HDL cholesterol levels. 54 Importantly, the transgene is under control of the human CETP promoter which has been shown to be directly regulated by LXR in human cells and in transgenic mice 55, 56 ( Figure VIIA and VIIB in the online-only Data Supplement). Indeed, treatment of CETP transgenic mice with T0901317 decreases HDL cholesterol by ≈25% and raises the amount of cholesterol associated with apolipoprotein B-containing lipoprotein particles ( Figure 5A and 5B and Table) . To determine the effect of CETP expression on RCT in vivo, CETP transgenic mice and littermate controls were treated with vehicle or T0901317 and injected with 3 H-cholesterol-loaded C57BL/6J (LXR + ) bone marrowderived macrophages as described in previous experiments. Consistent with a critical role for HDL in promoting the accumulation of macrophage-derived cholesterol in plasma, the amount of 3 H-cholesterol in this compartment at 24 and 48 hours is significantly reduced in CETP transgenic mice and the ability of T0901317 to increase plasma cholesterol accumulation is lost ( Figure 5C ). Similarly, unfractionated plasma and FPLC-purified HDL particles from T0901317-treated CETP transgenic mice do not exhibit increased efflux activity as is observed in nontransgenic controls ( Figure 5D and 5E). The ability of LXR agonists to increase HDL phospholipids, however, is not impaired in CETP transgenics ( Figure VIIC upregulation of CETP expression counters the ability of agonists to enhance the appearance of macrophage-derived cholesterol in the plasma. In contrast to the inhibitory effect of CETP expression on the accumulation of macrophage-derived cholesterol in plasma, LXR agonist treatment increases fecal 3 H-sterol levels in both CETP transgenic and littermate controls ( Figure 5F ). Interestingly, CETP expression also results in a significant increase in fecal bile acids in vehicle-treated animals ( Figure VIID in the online-only Data Supplement). Increased bile acid synthesis has previously been reported in CETP transgenic mice. 57, 58 Little or no difference was observed in hepatic 3 H-cholesterol levels among the groups (data not shown). Thus, as observed with the LXRα liverspecific knockout (LivKO) mice, it is possible to functionally sever the transfer of macrophage-derived cholesterol to the plasma from subsequent fecal excretion.
Discussion
The discovery that LXR agonists can promote macrophage cholesterol efflux in vitro via direct regulation of the genes encoding ABCA1, ABCG1, and apolipoprotein E 22, 59 suggested a simple hypothesis for the cardioprotective effect of LXR activation based on promoting cholesterol transfer from macrophage foam cells to HDL, the first step in the RCT pathway. This hypothesis is supported by the finding that macrophage LXR activity is required for the antiatherogenic activity of LXR agonists. 38 Combining in vitro cholesterol efflux measurements, in vivo RCT assays, and tissue-specific LXR knockouts, we now demonstrate that the ability of LXR agonists to stimulate RCT in vivo defined as the transfer of macrophage-derived cholesterol to the feces is largely independent of macrophage LXR activity ( Figure 6 ). Thus, macrophage LXRs are neither necessary nor sufficient for LXR agonists to increase RCT, at least when measured in an acute assay during a 48-hour time course. Additionally, our studies suggest that it is the ability of LXR agonists to increase HDL biogenesis and to improve HDL functional activity that is largely responsible for stimulating the appearance of macrophage-derived cholesterol in plasma ( Figure 6 ). The LXR agonist used in Figure 5 . Cholesteryl ester transfer protein (CETP) inhibits liver X receptor agonist-dependent reverse cholesterol transport. CETP − (A) and CETP + (B) mice (n=6/group) were treated with vehicle or T0901317 (10 milligram/killogram) for 5 days, plasma was pooled, subjected to fast liquid protein chromatography (FPLC), and the cholesterol content of each fraction was measured as described in Materials and Methods in the online-only Data Supplement.
3 H-cholesterol and acetylated low-density lipoprotein-loaded C67BL/6 bone marrow-derived macrophages (BMMs) were injected into CETP − and CETP + mice (n=6/group) treated with vehicle or T0901317, and the amount of 3 H-sterol in plasma (C) and feces (F) was determined as described in Materials and Methods in the online-only Data Supplement. Raw 264.7 cells were incubated with 0.03% pooled plasma (D) or FPLC-purified high-density lipoprotein (HDL; E) from vehicle-or T0901317-treated CETP − and CETP + mice (n=5/group), and cholesterol efflux was measured as described in Materials and Methods in the online-only Data Supplement. Efflux data are representative of 3 independent experiments. Data are mean±SEM. *Statistically significant difference between vehicle-and T0901317-treated animals of the same genotype (P≤0.05%). †Statistically significant difference between CETP − and CETP + with the same treatment (P≤0.05%). CPM indicates counts per minute. these studies, T0901317, has been reported to modulate other nuclear receptors, at least in vitro. [60] [61] [62] Therefore, the possibility that another nuclear receptor, such as the pregnane X receptor, contributes to the activity of this molecule in vivo cannot be ruled out. All the activities of T0901317 measured in this work, however, are lost in cells and animals that are deficient in LXRs.
On a standard mouse chow diet, the ability of LXR agonists to stimulate the accumulation of macrophage-derived cholesterol in plasma is independent of LXR activity in both macrophages and the liver. Previous studies have determined that LXR agonists increase HDL cholesterol by inducing ABCA1 expression in the intestine. 34, 40, 63 Consistent with an important role for intestinal LXR activity in regulating RCT is the finding that selective activation of LXRs in the intestine using either a poorly absorbed intestine-specific LXR agonist 41 or intestine-specific transgenic overexpression of a hyperactive LXR (VP16-LXRα) 64 increases RCT when measured using assays similar to those described in this work. Furthermore, our studies indicate that intestinal LXR activation can increase the cholesterol acceptor activity of HDL particles ( Figure 6 ) most likely by increasing the production of immature nascent particles that have been shown to be preferred cholesterol acceptors. [65] [66] [67] Interestingly, this work also describes a potential role for LXR activity in white adipose in regulating cholesterol trafficking.
To test the hypothesis that agonist-dependent increases in HDL mass and function drive the accumulation of macrophage-derived cholesterol in plasma during RCT assays, we took advantage of the observation that the ability of LXR agonists to raise HDL cholesterol is lost in CETP transgenic mice. 53, 56 CETP, an enzyme that transfers cholesterol esters from HDL to apolipoprotein B-containing lipoprotein particles in exchange for triglycerides, is not expressed in rodents, but the human gene used in this study is regulated by LXRs. 55, 56, 68 Importantly, CETP activity in the plasma is increased after LXR agonist treatment, HDL levels are lowered, and plasma cholesterol accumulation measured during RCT assays is decreased. The cholesterol acceptor activity of unfractionated plasma and FPLC-purified HDL from T0901317-treated CETP transgenic mice is also reduced relative to nontransgenic controls. Finally, the conclusion that increasing CETP activity impairs HDL particle function is consistent with reports that inhibition of CETP activity improves the cholesterol acceptor activity of human HDL particles. 69 Taken together, the data support the hypothesis that the ability of LXR agonists to increase the accumulation of macrophage-derived cholesterol in plasma is primarily determined by the quantity and quality of the HDL particles. Nevertheless, in CETP transgenic animals, LXR agonist treatment still increases fecal excretion of macrophage-derived cholesterol. Therefore, we cannot rule out the possibility that CETP expression decreases the levels of macrophage-derived cholesterol in plasma by increasing hepatic clearance via receptors for apolipoprotein B-containing particles. Similar to CETP expression, Bi et al 63 found that liver-specific deletion of Abca1 reduces plasma HDL levels and decreases plasma accumulation of 3 H-cholesterol in RCT assays without altering fecal sterol excretion. Bi et al 63 suggest that the small plasma HDL pool that remains in the liver Abca1 knockout mice may be quantitatively sufficient to mediate the transport of macrophage-derived cholesterol to the liver for excretion. Our study with CETP transgenic mice together with the work of Bi et al 63 raises the possibility, at least under these experimental conditions, that the appearance of macrophage-derived cholesterol in the plasma is a not a rate-limiting step for fecal cholesterol excretion.
In contrast to CETP transgenic expression, liver-specific deletion of LXRα (LivKO) has little or no effect on the accumulation of macrophage-derived cholesterol in plasma (on a standard chow diet) but strongly inhibits LXR agonist-stimulated fecal cholesterol excretion ( Figure 6 ). Thus, our analysis of CETP transgenic and LXRα LivKO mice indicates that it is possible to functionally separate plasma cholesterol accumulation from fecal excretion. Plasma cholesterol accumulation is primarily controlled by the ability of LXRs to regulate the quantity and quality of HDL, whereas fecal excretion is controlled by LXR-dependent regulation of hepatic ABCG5 and ABCG8 levels, allowing a single transcription factor pair (LXRα and LXRβ) to coordinate cholesterol movement throughout the body. These results raise the question regarding the potential therapeutic benefit of regulating either macrophage cholesterol efflux or fecal excretion independently. Current therapeutic approaches for atherosclerotic CVD all involve reducing LDL cholesterol in the blood. Therefore, if increasing fecal cholesterol excretion ultimately reduces plasma LDL levels, one might predict a therapeutic benefit. On the contrary, APOA Milano and other APOA1-derived peptides have been shown to increase macrophage cholesterol efflux and to improve cardiovascular end points, although it not clear that the beneficial effects of these agents are dependent on promoting cholesterol efflux. 70, 71 Future studies that, for instance, combine macrophage-selective overexpression of ABCA1 with LXR liver-specific knockouts may be a way to address the therapeutic benefits of increased macrophage efflux in the absence of fecal cholesterol excretion.
Interestingly, the contribution of liver LXR activity to RCT can be influenced by the cholesterol content of the diet. As described above, on a standard mouse chow diet, knocking out LXRα in the liver has little or no effect on the accumulation of macrophage-derived cholesterol in plasma while completely eliminating agonist-stimulated fecal excretion ( Figure 6 ). When cholesterol (0.2%) is added to the diet, however, LXR agonist-dependent plasma cholesterol accumulation is significantly decreased in LivKO mice. The absence of agonistdependent accumulation of macrophage-derived cholesterol in plasma when cholesterol is included in the diet correlates with the inability of agonist treatment to increase HDL cholesterol and improve the acceptor capacity of purified HDL in LivKO mice under these conditions. LXR agonist treatment still increases ABCA1 expression in the intestines of LivKO on the 0.2% cholesterol diet, and the reason(s) why HDL cholesterol levels are not increased in these mice remains to be determined. Compared with littermate floxed controls on the 0.2% cholesterol diet, LivKO mice have increased hepatic cholesterol levels although we did not detect any evidence for increased hepatic inflammation, endoplasmic reticulum stress, or liver damage in these mice. We /Lxrβ −/− mice are resistant to high-fat diet-induced obesity; however, this resistance is only observed when the high-fat diet also contains cholesterol. These observations raise the possibility that hepatic cholesterol accumulation leads to the generation of a paracrine signal that can influence lipid metabolism in other tissues.
Bone marrow transplantation experiments and overexpression studies indicate that macrophages are the site of LXR agonist-dependent antiatherogenic activity. 38, 42, 43 The studies described in this work, however, indicate that macrophage LXR activity does not make a significant contribution to RCT. Similarly, using LivKO mice in a severe hyperlipidemic environment (Ldlr
+Western diet), we demonstrated that LXR agonists can reduce atherosclerosis without increasing RCT. 34 Kappus et al 74 also reached an analogous conclusion in a recent study using mice with myeloid-specific double knockout of Abca1 and Abcg1. Together, these observations suggest that although hematopoietic LXR expression is required for the beneficial effects of LXR agonists, an increase in RCT or macrophage efflux is not. LXR activation inhibits nuclear factor κβ signaling suggesting decreased inflammation as an obvious mechanism for LXR-dependent antiatherogenic activity. 75, 76 A dominant role for anti-inflammatory activity as the beneficial effect of LXR activation on atherosclerosis has important implications for the potential therapeutic use of LXR agonists. In particular, in vitro experiments have suggested that LXR agonists can have proinflammatory activities in human macrophages 77 in contrast to the anti-inflammatory effects measured in rodents. Additionally, as described above, preclinical studies examining the antiatherogenic activity of LXR ligands generally have been performed under severe hyperlipidemic conditions where the ability of LXR agonists to increase HDL mass is lost. 34, 37, 78 Because human CVD patients do not usually present with the supraphysiological plasma cholesterol levels observed in genetic mouse models, the ability of LXR agonists to stimulate RCT may be maintained in humans and could be therapeutic. As we observe in CETP transgenic mice, however, the ability of LXR agonists to increase HDL cholesterol seems to be lost in nonhuman primates that express CETP. 79, 80 Recent clinical trials with niacin 7 and CETP inhibitors 6 have called into question the hypothesis that raising HDL cholesterol has beneficial effects on human CVD. The clinical trials together with experiments suggesting that the cholesterol acceptor activity of HDL isolated from patients can be a more accurate measurement of CVD risk have led to the proposal that assessing HDL function may be more relevant than measurements of HDL cholesterol mass. 9, 15, 20 Along with increasing the levels of HDL cholesterol, LXR agonist treatment also increases the cholesterol acceptor activity of HDL particles that were normalized by the quantity of APOA1. HDL particles are heterogeneous in size and composition making it difficult to discern the LXR-dependent modifications that improve cholesterol acceptor activity. Nevertheless, our initial analysis of HDL particle composition found increased levels of phospholipids (normalized to APOA1) in the HDL particles purified from agonist-treated animals. The phospholipid:APOA1 ratio in HDL has been shown to be an important determining factor in predicting macrophage efflux. Studies using mice and rats expressing human APOA1 indicate that the prime component of HDL that modulates cholesterol efflux is HDL phospholipid. 81, 82 Furthermore, the correlation between macrophage cholesterol efflux and HDL phospholipid in human sera is stronger than with any other measured lipoprotein parameter, including HDL cholesterol, APOA1, and triglycerides. 48 CETP expression, however, seems to impact HDL function without modulating phospholipid levels, suggesting that multiple components of HDL can influence particle function. LXRs likely regulate multiple pathways that modulate HDL activity, and future studies using detailed lipidomic and proteomic approaches can be used to further define the LXRdependent changes in HDL composition that regulate HDL particle function. These studies that define particle function may open the door to new therapeutic approaches for targeting HDL.
